All In Biotech

Drug Trial Radar · NCT06915142

A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour

An Phase II Clinical Study on the Safety, Tolerability and Efficacy of HRS-7058 in Combination With Antitumor Drugs in Subjects With Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Apr 28, 2025

Primary completion

Dec 2026

Study completion Oct 2027

Sponsor

Sponsor type
Industry
First posted
Apr 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicentre, open phase II clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in combination with antitumor drugs in subjects with advanced malignant tumour. To evaluate the safety, tolerability and efficacy of HRS-7058 in combination with antitumor drugs.

Conditions

  • Advanced Malignant Tumour

Interventions

  • HRS-7058 + SHR-1316Drug

    HRS-7058 + SHR-1316

  • HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapyDrug

    HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy

  • HRS-7058 + CetuximabDrug

    HRS-7058 + Cetuximab

  • HRS-7058 + SHR-1826Drug

    HRS-7058 + SHR-1826

  • HRS-7058 + SHR-1826 + SHR-1316Drug

    HRS-7058 + SHR-1826 + SHR-1316

  • HRS-7058 + SHR-A1202Drug

    HRS-7058 + SHR-A1202

  • HRS-7058 + BP102Drug

    HRS-7058 + BP102

  • HRS-7058 + SHR-9839Drug

    HRS-7058 + SHR-9839

  • HRS-7058 +SHR-A2102 +SHR-1316Drug

    HRS-7058 +SHR-A2102 +SHR-1316

  • HRS-7058 +SHR-9839(sc)+SHR-1316Drug

    HRS-7058 +SHR-9839(sc)+SHR-1316

  • HRS-7058 +SHR-1316 +BP102Drug

    HRS-7058 +SHR-1316 +BP102

  • HRS-7058 +SHR-A2102 +BP102Drug

    HRS-7058 +SHR-A2102 +BP102

  • HRS-7058 +SHR-A2102 +SHR-1316 +BP102Drug

    HRS-7058 +SHR-A2102 +SHR-1316 +BP102

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT) (Dose Escalation and Dose Expansion)Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months
  2. Safety endpoints: adverse events (AE) (Dose Escalation and Dose Expansion)Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months]
  3. Phase II recommended dose (RP2D)(Dose Escalation and Dose Expansion)Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months]
  4. Efficacy endpoints: Objective response rate (ORR) assessed based on RECIST v1.1 criterion (Efficacy Expansion)Time frame: From the beginning of first patient in (FPI) to the end of study up to approximately 32 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Beijing Municipality, China · Recruiting

  • Tianjin Cancer Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.